Why the study?
Does asymmetric dimethylarginine (ADMA) predict overall mortality in hemodialysis patients?
Does asymmetric dimethylarginine (ADMA) predict overall mortality in hemodialysis patients?
Although ADMA statistically predicts overall mortality in hemodialysis patients, its clinical utility is limited due to minimal absolute differences between survivors and non-survivors.
Answers are grounded in this paper and cite their sources.
ADMA association with mortality in hemodialysis should not change practice; leaves open its value as a prognostic biomarker pending prospective studies.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Cibulka et al. (2007) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: